Novo Nordisk's Q1 2026 Profit Surge Masked by Underlying Sales Decline
Event summary
- Novo Nordisk's Q1 2026 adjusted operating profit reached DKK 32,858 million, up 65% reported but down 6% at CER excluding a USD 4.2 billion 340B provision reversal.
- Adjusted sales excluding the provision decreased 4% at CER, with US operations down 11% due to lower realized prices despite Wegovy® volume growth.
- Wegovy® pill prescriptions exceeded 200,000 weekly in the US, with total prescriptions surpassing 2 million since launch.
- FDA approved Wegovy® HD (7.2 mg) in March 2026, showing 20.7% mean weight loss in trials.
- 2026 outlook raised: adjusted sales and operating profit growth now expected at -4% to -12% at CER.
The big picture
Novo Nordisk's Q1 2026 results highlight the tension between strong GLP-1 product momentum and US pricing challenges. The 340B provision reversal inflated reported profits, but underlying sales declines signal broader industry pressures on drug pricing. The company's ability to expand Wegovy® internationally and advance its pipeline will be critical in sustaining growth amid regulatory and market headwinds.
What we're watching
- Pricing Dynamics
- How sustained US pricing pressure will affect Novo Nordisk's profitability despite strong Wegovy® volume growth.
- International Expansion
- The pace at which Wegovy® pill launches outside the US can offset declining US sales.
- Pipeline Progress
- Whether zenagamtide and Awiqli® approvals can diversify revenue streams beyond obesity and diabetes.
Related topics